<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259334</url>
  </required_header>
  <id_info>
    <org_study_id>SHP647-301</org_study_id>
    <secondary_id>2017-000599-27</secondary_id>
    <nct_id>NCT03259334</nct_id>
  </id_info>
  <brief_title>A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based
      on composite score of patient-reported symptoms and centrally read endoscopy, in subjects
      with moderate to severe ulcerative colitis (UC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Anticipated">November 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Remission at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Remission is defined as a composite score of patient-reported symptoms using daily e-diary and centrally read endoscopy as stool frequency subscore of 0 or 1 with at least a 1-point change from baseline, rectal bleeding subscore of 0 and endoscopic subscore of 0 or 1 (modified, excludes friability). The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); Physician global assessment (PGA, 0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Endoscopic Remission at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Remission at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission is defined by stool frequency subscore of 0 or 1 with at least a 1-point change from baseline in stool frequency subscore, and rectal bleeding subscore of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Response (Composite) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical response (composite) is defined as a decrease from baseline in the composite score of patient-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding greater than or equal to (&gt;=) 1 point or a subscore for rectal bleeding less than or equal to (&lt;=) 1. The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mucosal Healing at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of &lt;=2. The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">825</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>SHP647 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 25 milligram (mg) of SHP647 subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4, and Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP647 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 75 mg of SHP647 SC injection using PFS on Week 0, Week 4, and Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to SHP647 SC injection using PFS on Week 0, Week 4, and Week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP647</intervention_name>
    <description>1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).</description>
    <arm_group_label>SHP647 25 mg</arm_group_label>
    <arm_group_label>SHP647 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 mL of sterile aqueous buffered solution.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to be eligible for enrollment
        into the study.

          1. Subjects and/or their parent or legally authorized representative must have an
             understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          2. Subjects must be able to voluntarily provide written, signed, and dated (personally or
             via a legally authorized representative) informed consent and/or assent, as
             applicable, to participate in the study.

          3. Subjects must be between 16 and 80 years of age at the time of the signing of the
             informed consent/assent form.

             NOTE: Subjects less than (&lt;) 18 years of age must weigh greater than or equal to (&gt;=)
             40 kg and must have body mass index (BMI) &gt;=16.5.

          4. Subjects must have a documented diagnosis (radiologic or endoscopic with histology) of
             UC for &gt;=3 months before screening. The following must be available in each subject's
             source documentation:

               -  A biopsy report to confirm the histological diagnosis.

               -  A report documenting disease duration based upon prior colonoscopy. NOTE: If this
                  documentation is not available at the time of screening, a colonoscopy with
                  biopsy to confirm the diagnosis is required during the screening period.

          5. Subjects must be willing to undergo a flexible sigmoidoscopy or colonoscopy (if
             preferred), including biopsy sample collection, during screening after all other
             inclusion criteria have been met.

          6. Subjects must have moderate to severe active UC, defined as a total Mayo score of &gt;=6,
             including a centrally read endoscopic subscore &gt;=2, rectal bleeding subscore &gt;=1, and
             stool frequency subscore &gt;=1 at baseline (Visit 2).

          7. Subjects must have evidence of UC extending proximal to the rectum ( that is [ie,]not
             limited to proctitis).

          8. Subjects must have had an inadequate response to, or lost response to, at least 1
             conventional treatment such as mesalamine (5-aminosalicylate [ASA]), glucocorticoids,
             immunosuppressants (azathioprine [AZA], 6-mercaptopurine [6-MP], or methotrexate
             [MTX]), or anti-tumor necrosis factor (TNF).

          9. Subjects receiving any treatment(s) for UC are eligible provided they have been, and
             are anticipated to be, on a stable dose for the designated period of time.

         10. Subjects are males or nonpregnant, nonlactating females who, if sexually active, agree
             to comply with the contraceptive requirements of the protocol, or females of
             nonchildbearing potential. Males and females of reproductive potential who are
             sexually active must agree to use acceptable contraception for the duration of the
             study.

        Exclusion Criteria:

        Subjects are excluded from the study if any of the following exclusion criteria are met.

          1. Subjects with indeterminate colitis, microscopic colitis, ischemic colitis, infectious
             colitis, or clinical/histologic findings suggestive of Crohn's disease.

          2. Subjects with colonic dysplasia or neoplasia. (Subjects with prior history of
             adenomatous polyps will be eligible if the polyps have been completely removed.)

          3. Subjects with past medical history or presence of toxic megacolon.

          4. Subjects with colonic stricture, past medical history of colonic resection, a history
             of bowel surgery within 6 months before screening, or who are likely to require
             surgery for UC during the treatment period.

          5. Subjects at risk for colorectal cancer must have a colonoscopy performed during the
             screening period with results available within 10 days before the baseline visit
             (Visit 2), unless the subject has had a colonoscopy within 1 year prior to screening,
             and any adenomatous polyps found at that examination have been excised. Colonoscopy
             report and pathology report (if biopsies are obtained) from the colonoscopy performed
             during screening or in the prior year must be available in the source documents.

             Subjects at risk for colorectal cancer include, but are not limited to:

               -  Subjects with extensive colitis for &gt;=8 years or disease limited to left side of
                  colon (ie, distal to splenic flexure) for &gt;=10 years before screening, regardless
                  of age.

               -  Subjects &gt;=50 years of age at the time of signing of the informed consent form.

          6. Subjects have had prior treatment with SHP647 (formerly PF-00547659).

          7. Subjects with known or suspected intolerance or hypersensitivity to the
             investigational product(s), closely related compounds, or any of the stated
             ingredients.

          8. Subjects have received anti-TNF treatment within 60 days before baseline (Visit 2).

          9. Subjects have received any biologic with immunomodulatory properties (other than
             anti-TNFs) within 90 days before baseline (Visit 2).

         10. Subjects have ever received anti-integrin/adhesion molecule treatment (example:
             natalizumab, vedolizumab, efalizumab, etrolizumab, or any other investigational
             anti-integrin/adhesion molecule).

         11. Subjects have received parenteral or rectal glucocorticoids, or rectal 5-ASA, within
             14 days before screening endoscopic procedure.

         12. Subjects have participated in other investigational studies within either 30 days or 5
             half-lives of investigational product used in the study (whichever is longer) before
             baseline (Visit 2).

         13. Subjects have received a live (attenuated) vaccine within 30 days before the baseline
             visit (Visit 2).

         14. Subjects with active enteric infections (positive stool culture and sensitivity),
             Clostridium difficile infection or pseudomembranous colitis [subjects with C.
             difficile infection at screening may be allowed re-test after treatment], evidence of
             active cytomegalovirus infection or Listeria monocytogenes, known active invasive
             fungal infections such as histoplasmosis or parasitic infections, clinically
             significant underlying disease that could predispose the subjects to infections, or a
             history of serious infection (requiring parenteral antibiotic and/or hospitalization)
             within 4 weeks before the baseline visit (Visit 2).

         15. Subjects with abnormal chest x-ray findings at screening (Visit 1), such as presence
             of active tuberculosis (TB), general infections, heart failure, or malignancy. (A
             chest x-ray performed up to 12 weeks before study entry [screening, Visit 1] may be
             used if available; documentation of the official reading must be located and available
             in the source documentation.)

         16. Subjects with evidence of active or latent infection with Mycobacterium tuberculosis
             (TB) who have not completed a generally accepted full course of treatment before
             randomization are excluded. All other subjects must have either the Mantoux (purified
             protein derivative [PPD]) tuberculin skin test or interferon gamma release assay
             (IGRA) performed.

             Subjects who have no history of previously diagnosed active or latent tuberculosis are
             excluded if they have a positive Mantoux (PPD) tuberculin skin test (ie &gt;=5 millimeter
             [mm] induration) or a positive IGRA (the latter to be tested at the site's local
             laboratory) during screening or within 12 weeks before randomization. If IGRA test
             cannot be performed locally, a central laboratory may be used, with prior agreement
             from the sponsor.

               -  An IGRA is strongly recommended for subjects with a prior Bacillus
                  Calmette-Guerin (BCG) vaccination, but may be used for any subject. Documentation
                  of IGRA product used and the test result must be in the subject's source
                  documentation if performed locally. Acceptable IGRA products include Quantiferon
                  TB Gold In-Tube Test.

               -  If the results of the IGRA are indeterminate, the test may be repeated, and if a
                  negative result is obtained, enrollment may proceed. In subjects with no history
                  of treated active or latent tuberculosis, a positive test on repeat will exclude
                  the subject. Subjects with a history of active or latent tuberculosis infection
                  must follow instructions for &quot;Subjects with a prior diagnosis of active or latent
                  tuberculosis are excluded unless both of the following criteria are met&quot; in this
                  criterion.

               -  Subjects with repeat indeterminate IGRA results, with no prior TB history, may be
                  enrolled after consultation with a pulmonary or infectious disease specialist who
                  determines low risk of infection (ie, subject would be acceptable for
                  immunosuppressant [eg, anti-TNF] treatment without additional action). This
                  consultation must be included in source documentation.

             Results from a chest x-ray, taken within the 3 months before or during screening
             (Visit 1) must show no abnormalities suggestive of active TB infection as determined
             by a qualified medical specialist.

             Subjects with a prior diagnosis of active or latent tuberculosis are excluded unless
             both of the following criteria are met:

               -  The subject has previously received an adequate course of treatment for either
                  latent (eg, 9 months of isoniazid or an acceptable alternative regimen, in a
                  locale where rates of primary multidrug TB resistance are less than (&lt;) 5%.
                  Subjects from regions with higher rates of primary multidrug TB resistance are
                  excluded) or active (acceptable multidrug regimen) TB infection. Evidence of
                  diagnosis and treatment must be included in source documentation. Consultation
                  with a pulmonary or infectious disease specialist to confirm adequate treatment
                  (ie, subject would be acceptable for immunosuppressant [eg, anti-TNF] treatment
                  without additional action) must be performed during the screening period. The
                  consultation report must be included in source documentation prior to enrollment.

               -  A chest x-ray performed within 3 months prior to screening (Visit 1) or during
                  screening (Visit 1) indicates no evidence of active or recurrent disease, and
                  documentation of interpretation by a qualified medical specialist must be
                  included in source documentation.

         17. Subjects with a pre-existing demyelinating disorder such as multiple sclerosis or new
             onset seizures, unexplained sensory motor, or cognitive behavioral, neurological
             deficits, or significant abnormalities noted during screening.

         18. Subjects with any unexplained symptoms suggestive of progressive multifocal
             leukoencephalopathy (PML) based on the targeted neurological assessment during the
             screening period.

         19. Subjects with a transplanted organ. Skin grafts to treat pyoderma gangrenosum are
             allowed.

         20. Subjects with a significant concurrent medical condition at the time of screening
             (Visit 1) or baseline (Visit 2), including, but not limited to, the following:

               -  Any major illness/condition or evidence of an unstable clinical condition (eg,
                  renal, hepatic, hematologic, gastrointestinal (except disease under study),
                  endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or
                  local active infection/infectious illness) that, in the investigator's judgment
                  will substantially increase the risk to the subject if he or she participates in
                  the study.

               -  Cancer or history of cancer or lymphoproliferative disease within the previous 5
                  years (other than resected cutaneous basal cell carcinoma, squamous cell
                  carcinoma, or carcinoma in situ of the uterine cervix that has been treated with
                  no evidence of recurrence).

               -  Presence of acute coronary syndrome (eg, acute myocardial infarction, unstable
                  angina pectoris) within 24 weeks before screening (Visit 1).

               -  History of significant cerebrovascular disease within 24 weeks before screening
                  (Visit 1).

         21. Subjects who have had significant trauma or major surgery within 4 weeks before the
             screening visit (Visit 1), or with any major elective surgery scheduled to occur
             during the study.

         22. Subjects with evidence of or suspected liver disease, liver injury due to methotrexate
             or primary sclerosing cholangitis.

         23. Subjects with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B
             core antibody (HBcAb). NOTE: if a subject tests negative for HBsAg, but positive for
             HBcAb, the subject would be considered eligible if the subject tests positive for
             antibody to Hepatitis B surface antigen (HBsAb also referred as anti-HBsAg) reflex
             testing.

         24. Subjects with positive hepatitis C antibody (HCVAb) with confirmation by
             HCV-ribonucleic acid (RNA) polymerase chain reaction (PCR) reflex testing.

         25. Subjects with any of the following abnormalities in hematology and/or serum chemistry
             profiles during screening. NOTE: Screening laboratory tests, if the results are
             considered by the investigator to be transient and inconsistent with the subject's
             clinical condition, may be repeated once during the screening period for confirmation.
             Results must be reviewed for eligibility prior to the screening endoscopy procedure.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels &gt;=2.0
                  times the upper limit of normal (ULN).

               -  Total bilirubin level &gt;=1.5 times the ULN (except in subjects with documented
                  diagnosis of Gilbert's syndrome).

               -  Hemoglobin level less than or equal to (&lt;=) 80 gram per liter (g/L) (8.0 gram per
                  deciliter [g/dL]).

               -  Platelet count &lt;=100 × 109 per liter (/L) (100,000 cells per cubicmillimeter
                  [/mm^3]) or &gt;=1000 × 109/L (1,000,000 cells/mm^3).

               -  White blood cell count &lt;=3.5 × 109/L (3500 cells/mm^3).

               -  Absolute neutrophil count (ANC) &lt;2000 cells/mm^3.

               -  Serum creatinine level &gt;=177 micromoles per liter [mcmol/L] (2 mg/dL) or
                  estimated glomerular filtration rate (GFR) &lt;40 ml/min/1.73m^2 based on the
                  abbreviated MDRD.

         26. Subjects with known infection with human immunodeficiency virus (HIV).

         27. Subjects who have, or who have a history of (within 2 years before screening [Visit
             1]), serious psychiatric disease, alcohol dependency, or substance/drug abuse.

         28. Subjects using medicinal marijuana (cannabis) or related products for recreational
             purposes, who have a known dependency per the criteria in the Diagnostic and
             Statistical Manual of Mental Disorders, Edition 5 (including urine drug screen and
             medical history). Exceptions are those subjects who are prescribed marijuana (by a
             physician) for medicinal use and where the product is sourced from a licensed
             pharmacy/provider. Such subjects must be using the product, in a stable regimen, for
             at least 3 months before screening.

         29. Subjects with any other severe acute or chronic medical or psychiatric condition or
             laboratory or ECG abnormality that may increase the risk associated with study
             participation or investigational product administration or may interfere with the
             interpretation of study results and, in the judgment of the investigator, would make
             the subject inappropriate for entry into this study.

         30. Female subjects who are planning to become pregnant during the study period.

         31. Male subjects who are planning to donate sperm must agree not to do so for the
             duration of the study and through 16 weeks after last dose of investigational product.

         32. Subjects who are investigational site staff members or relatives of those site staff
             members or subjects who are Shire employees directly involved in the conduct of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>1 866-842-5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mesa Gastrointestinal Associates</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sumir Patel</last_name>
    </contact>
    <investigator>
      <last_name>Sumir Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Digestive Health</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chirag Trivedi</last_name>
      <phone>623-237-0939</phone>
      <email>ctrivedi@arizonadigestivehealth.com</email>
    </contact>
    <investigator>
      <last_name>Chirag Trivedi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Gottlieb</last_name>
      <phone>520-257-3881</phone>
      <email>ggottlieb@delsolresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gary Gottlieb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atria Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meenakshi Budhraja</last_name>
      <phone>501-492-9175</phone>
      <email>drMeb@atriaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Meenakshi Budhraja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Om Research LLC</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jatinder Pruthi</last_name>
      <phone>310-684-2494</phone>
      <email>jpruthi@synergistresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jatinder Pruthi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Lee</last_name>
      <phone>562-826-5628</phone>
    </contact>
    <investigator>
      <last_name>Robert Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Padua</last_name>
    </contact>
    <investigator>
      <last_name>David Padua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeid Kayali</last_name>
      <phone>909-883-2999</phone>
      <email>zkayali@ieliverfoundation.com</email>
    </contact>
    <investigator>
      <last_name>Zeid Kayali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuren Medical and Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Penate Sr.</last_name>
      <phone>305-551-8493</phone>
      <email>penate@nurenmedical.com</email>
    </contact>
    <investigator>
      <last_name>Felix Penate Sr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Sarol</last_name>
      <phone>305-702-1594</phone>
      <email>juansarol@acrntrials.com</email>
    </contact>
    <investigator>
      <last_name>Juan Sarol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharma Research International Inc</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Meckstroth</last_name>
      <phone>239-631-2989</phone>
    </contact>
    <investigator>
      <last_name>Steven Meckstroth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwabena Ayesu</last_name>
      <phone>407-271-8030</phone>
      <email>kayesu@omegarcllc.com</email>
    </contact>
    <investigator>
      <last_name>Kwabena Ayesu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venkata Nath Iyunni</last_name>
      <phone>727-546-1680</phone>
    </contact>
    <investigator>
      <last_name>Venkata Nath Iyunni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research, LLC</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anis Ahmadi</last_name>
      <phone>904-824-1776</phone>
      <email>draahmadi3@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anis Ahmadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Steinbook</last_name>
      <phone>706-321-0495</phone>
      <email>newtrials@serrg.com</email>
    </contact>
    <investigator>
      <last_name>Michael Steinbook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Diseases, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pravinchandra Patel</last_name>
    </contact>
    <investigator>
      <last_name>Pravinchandra Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Hanauer</last_name>
      <phone>312-695-4929</phone>
      <email>shanauer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Hanauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Rubin</last_name>
      <phone>773-834-7414</phone>
      <email>drubin@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>David Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Dela Llana</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Dela Llana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laporte County Institute For Clinical Research</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minesh Patel</last_name>
      <phone>219-879-0333</phone>
      <email>minbeni1@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Minesh Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of SWLA LLC</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo McCall</last_name>
      <phone>337-493-5310</phone>
      <email>rmmclinicaltrials@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo McCall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humberto Aguilar</last_name>
      <phone>318-525-3233</phone>
      <email>haguilar@gis.md</email>
    </contact>
    <investigator>
      <last_name>Humberto Aguilar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashwin Ananthakrishnan</last_name>
      <phone>617-724-3238</phone>
      <email>aananthakrishnan@partners.org</email>
    </contact>
    <investigator>
      <last_name>Ashwin Ananthakrishnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Health Center PA</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfred McNair, Jr.</last_name>
      <phone>228-872-7612</phone>
      <email>lbrowndhc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alfred McNair, Jr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Biomedical Research Foundation - NAVREF</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarun Rai</last_name>
      <phone>816-861-4700</phone>
      <phone_ext>52475</phone_ext>
      <email>tarun.rai@va.gov</email>
    </contact>
    <investigator>
      <last_name>Tarun Rai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Friedrich, Rubin, Panella, Sapienza, and Kaplounov, LLP</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth Rubin</last_name>
      <phone>201-569-7044</phone>
      <email>scopemd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consultants For Clinical Research Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pradeep Bekal</last_name>
      <phone>513-872-4549</phone>
      <email>pbekal@aol.com</email>
    </contact>
    <investigator>
      <last_name>Pradeep Bekal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Center For Digestive Health</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra El-Hachem</last_name>
      <phone>412-359-8900</phone>
      <email>sandra.elhachem@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Sandra El-Hachem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziad Younes</last_name>
      <phone>901-820-0090</phone>
      <email>zyounes@gastro1.com</email>
    </contact>
    <investigator>
      <last_name>Ziad Younes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Beaulieu</last_name>
      <phone>615-322-4643</phone>
    </contact>
    <investigator>
      <last_name>Dawn Beaulieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Gastro</name>
      <address>
        <city>Union City</city>
        <state>Tennessee</state>
        <zip>38261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kofi Nuako</last_name>
      <phone>731-884-0600</phone>
      <email>zeepascal@aol.com</email>
    </contact>
    <investigator>
      <last_name>Kofi Nuako</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manreet Kaur</last_name>
      <phone>713-798-6342</phone>
      <email>manreet.kaur@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Manreet Kaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Irfan</last_name>
      <phone>281-517-0550</phone>
      <email>drmirfan2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad Irfan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research/Coastal Gastroenterology Associates, PA</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advitya Malhotra</last_name>
      <phone>281-557-2527</phone>
    </contact>
    <investigator>
      <last_name>Advitya Malhotra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Val Hansen MD</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Val Hansen</last_name>
      <phone>801-797-9315</phone>
      <email>valhansen@live.com</email>
    </contact>
    <investigator>
      <last_name>Val Hansen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Health Center at UWMC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Zisman</last_name>
      <phone>206-598-4377</phone>
      <email>tzisman@medicine.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Zisman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Lee</last_name>
      <phone>206-598-4377</phone>
      <email>leesd@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Franciscan Digestive Care Associates</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Larson</last_name>
      <phone>253-272-8664</phone>
      <email>stevenlarson@fhshealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Exemplar Research, Inc.</name>
      <address>
        <city>Elkins</city>
        <state>West Virginia</state>
        <zip>26241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitesh Ratnakar</last_name>
      <phone>304-216-2411</phone>
      <email>drratnakar@exemplarresearchinc.com</email>
    </contact>
    <investigator>
      <last_name>Nitesh Ratnakar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin Kupec</last_name>
      <phone>304-293-4123</phone>
      <email>jkupec@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Justin Kupec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Leong</last_name>
      <phone>+61297676111</phone>
      <email>rupert.leong@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Rupert Leong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Connor</last_name>
      <phone>+61287384085</phone>
      <email>Susan.Connor1@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Susan Connor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Hospital Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakob Begun</last_name>
      <phone>+61731638518</phone>
      <email>jakob.begun@mater.uq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Jakob Begun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Andrews</last_name>
      <phone>+61870742200</phone>
      <email>jane.andrews@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Jane Andrews</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miles Sparrow</last_name>
    </contact>
    <investigator>
      <last_name>Miles Sparrow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nik Ding</last_name>
      <phone>+61392312211</phone>
      <email>nik.ding@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Nik Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.ö. Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>St. Veit an der Glan</city>
        <state>Kärnten</state>
        <zip>9300</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Peter Gröchenig</last_name>
      <phone>+434212499130</phone>
    </contact>
    <investigator>
      <last_name>Hans Peter Gröchenig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LKH-Universitätsklinikum Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Högenauer</last_name>
      <phone>+43031638514388</phone>
      <email>christoph.hoegenauer@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Högenauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt Am Woerthersee</name>
      <address>
        <city>Klagenfurt am Wörthersee</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Peck-Radosavljevic</last_name>
      <phone>+4346353831103</phone>
      <email>markus@peck.at</email>
    </contact>
    <investigator>
      <last_name>Markus Peck-Radosavljevic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medizinische Privatuniversität</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonja Gassner</last_name>
      <phone>+435725557296</phone>
      <email>s.gassner@salk.at</email>
    </contact>
    <investigator>
      <last_name>Sonja Gassner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harald Hofer</last_name>
      <phone>+43072424152181</phone>
      <email>Harald.Hofer@klinikum-wegr.at</email>
    </contact>
    <investigator>
      <last_name>Harald Hofer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Walter Reinisch</last_name>
      <email>walter.reinisch@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Walter Reinisch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Goiano de Gastroenterologia E Endoscopia Digestiva Ltda</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74535-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Bafutto</last_name>
      <phone>+5562996862139</phone>
      <email>maurobafutto@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Mauro Bafutto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Da Cidade de Passo Fundo</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande Do Sul</state>
        <zip>99010-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ornella Cassol</last_name>
      <phone>+555491839440</phone>
      <email>pesquisahc@bioservsmo.com.br</email>
    </contact>
    <investigator>
      <last_name>Ornella Cassol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEMEC - Centro Multidisciplinar de Estudos Clínicos</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Boratto</last_name>
      <email>ctdfb@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Sandra Boratto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Klinichki Bolnicki Centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <state>Grad Zagreb</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marko Brinar</last_name>
    </contact>
    <investigator>
      <last_name>Marko Brinar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimir Borzan</last_name>
      <phone>+0038531511511</phone>
      <email>vborzan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Borzan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Virovitica</name>
      <address>
        <city>Virovitica</city>
        <zip>33000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matko Markotic</last_name>
    </contact>
    <investigator>
      <last_name>Matko Markotic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s. r. o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Vanasek</last_name>
      <phone>+420495218475</phone>
      <email>tomas.vanasek@hepato-gastro.com</email>
    </contact>
    <investigator>
      <last_name>Tomas Vanasek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut klinicke a experimentalni mediciny</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pavel Drastich</last_name>
      <phone>+420603869913</phone>
      <email>pavel.drastich@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Pavel Drastich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Baumgart</last_name>
      <phone>+4930450553277</phone>
      <email>daniel.baumgart@charite.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Baumgart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolff Schmiegel</last_name>
    </contact>
    <investigator>
      <last_name>Wolff Schmiegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna Dinter</last_name>
    </contact>
    <investigator>
      <last_name>Johanna Dinter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Boerner</last_name>
    </contact>
    <investigator>
      <last_name>Norbert Boerner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nazareth EMMS Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mahamid Mahmud</last_name>
    </contact>
    <investigator>
      <last_name>Mahamid Mahmud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eran Goldin</last_name>
    </contact>
    <investigator>
      <last_name>Eran Goldin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigal Fishman</last_name>
      <phone>+97236974468</phone>
      <email>sigalf@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Sigal Fishman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Rogai</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Rogai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietro Occhipinti</last_name>
    </contact>
    <investigator>
      <last_name>Pietro Occhipinti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complesso Integrato Columbus</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Armuzzi</last_name>
      <phone>+39063503310</phone>
      <email>alearmuzzi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alessandro Armuzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo Della Sofferenza IRCCS</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Bossa</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Bossa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kitasato University Kitasato Institute Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>108-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taku Kobayashi</last_name>
    </contact>
    <investigator>
      <last_name>Taku Kobayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Violeta Jakovlevaite</last_name>
      <phone>+370846396547</phone>
      <email>viletajak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Violeta Jakovlevaite</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geert D'Haens</last_name>
      <phone>+3215505011</phone>
      <email>g.dhaens@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Geert D'Haens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melita Medical</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-449</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Leszczyszyn</last_name>
      <phone>+48717072111</phone>
      <email>j.leszczyszyn@melitamedical.pl</email>
    </contact>
    <investigator>
      <last_name>Jaroslaw Leszczyszyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Lódz</city>
        <state>Lódzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elzbieta Czkwianianc</last_name>
      <phone>+48422711341</phone>
      <email>kpg@iczmp.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Elzbieta Czkwianianc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korczowski Bartosz, Gabinet Lekarski</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Korczowski</last_name>
      <phone>+48177404065</phone>
      <email>korczowski@op.pl</email>
    </contact>
    <investigator>
      <last_name>Bartosz Korczowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cluj Clinical County Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Lucian Dumitrascu</last_name>
      <phone>+40722756475</phone>
      <email>dan_dumitrascu@yahoo.de</email>
    </contact>
    <investigator>
      <last_name>Dan Lucian Dumitrascu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Company Hepatolog, LLC</name>
      <address>
        <city>Samara</city>
        <zip>443093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Malova</last_name>
      <phone>+78462502505</phone>
      <email>alenamalova@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Malova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center ''Bezanijska Kosa''</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mirjana Cvetkovic</last_name>
      <phone>+381641608353</phone>
      <email>mikialeksa5@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mirjana Cvetkovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <state>Šumadijski Okrug</state>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natasa Zdravkovic-Petrovic</last_name>
    </contact>
    <investigator>
      <last_name>Natasa Zdravkovic-Petrovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <state>Shropshire</state>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffery Butterworth</last_name>
      <phone>+441743261000</phone>
      <email>jeff.butterworth@sath.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jeffery Butterworth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

